Chemistry:RP-5063

From HandWiki
RP-5063
RP-5063.svg
Clinical data
Other namesRP-5000; Oxaripiprazole
Routes of
administration		By mouth
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
UNII
Chemical and physical data
FormulaC22H25Cl2N3O3
Molar mass450.36 g·mol−1
3D model (JSmol)

RP-5063, also known as RP-5000, is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder.[1][2][3][4] Reviva Pharmaceuticals also intends to investigate RP-5063 for the treatment of bipolar disorder, major depressive disorder, psychosis/agitation associated with Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder (ADD/ADHD), and autism.[5][6] As of May 2015, it is in phase III clinical trials for schizophrenia.[5][6]

Pharmacology

Pharmacodynamics

RP-5063 is described as a so-called "dopamine-serotonin system stabilizer" due to its unique actions on the dopamine and serotonin neurotransmitter systems compared to other antipsychotics.[4][7] Specifically, it acts as a partial agonist of the D2, D3, and D4 receptors and of the 5-HT1A and 5-HT2A receptors, and as an antagonist of the 5-HT6 and 5-HT7 receptors.[3][4][7] RP-5063 has high affinity for the D2S, D2L, D3, D4.4, 5-HT1A, 5-HT2A, 5-HT7, and H1 receptors, and moderate affinity for the D1, D5, 5-HT3, 5-HT6 receptors, the serotonin transporter, and the α1B-adrenergic receptor.[7] It lacks significant affinity for the 5-HT1B, 5-HT2C, α2-adrenergic, and muscarinic acetylcholine receptors, as well as for the norepinephrine and dopamine transporters.[7][8]

Chemistry

RP-5063 is identical to aripiprazole in chemical structure except for the replacement of one of the carbon atoms in aripiprazole's quinolinone ring system with an oxygen atom, resulting instead in a benzoxazinone ring system. The drug is also closely related structurally to brexpiprazole and cariprazine.

See also

References

  1. ↑ Medicines in Development for Mental Health (Report). Pharmaceutical Research and Manufacturers of America. 2014. p. 20. http://www.phrma.org/sites/default/files/pdf/2014-mental-health-report.pdf. Retrieved 2015-05-19. 
  2. ↑ Köster, Luisa-Sophie; Carbon, Maren; Correll, Christoph U (2014). "Emerging drugs for schizophrenia: an update". Expert Opinion on Emerging Drugs 19 (4): 511–531. doi:10.1517/14728214.2014.958148. ISSN 1472-8214. 
  3. ↑ 3.0 3.1 "Drug Development in Schizophrenia: Summary and Table". Pharmaceutical Medicine 28 (5): 265–271. 2014. doi:10.1007/s40290-014-0070-6. ISSN 1178-2595. 
  4. ↑ 4.0 4.1 4.2 Cantillon, Marc (2014). "Efficacy and Safety of Novel Dopamine Serotonin Stabilizer RP 5063 in Acute Schizophrenia and Schizoaffective Disorder". Schizophrenia Research 153: S22. doi:10.1016/S0920-9964(14)70070-2. ISSN 0920-9964. 
  5. ↑ 5.0 5.1 "About Us". Reviva Pharmaceuticals. http://revivapharma.com/about-us/. Retrieved 2015-05-19. 
  6. ↑ 6.0 6.1 "Product Pipeline". Reviva Pharmaceuticals. http://revivapharma.com/product_pipeline/. Retrieved 2015-05-19. 
  7. ↑ 7.0 7.1 7.2 7.3 Marc Cantillon, M.D., Mike Li, MS, Sarath Kanekal, Ph.D., DABT, RAC, Robert M.J. Ings, Ph.D., Grace Tung, RAC, Laxminarayan Bhat (2013). "Refresh: A Phase 2 RP5063 Efficacy and Safety in Schizophrenia and Schizoaffective Disorder". American Society of Clinical Psychopharmacology. http://ascpmeeting.org/wp-content/uploads/2014/10/Abstract-book-all-orals-FINAL-4_27_13.pdf. Retrieved 2015-05-19. 
  8. ↑ Reviva Pharmaceuticals (2012). "Reviva Pharmaceuticals Announces Enrollment of Patients in Phase 2 Clinical Study of RP5063 for the Treatment of Schizophrenia and Schizoaffective Disorder". PipelineReview. http://www.pipelinereview.com/index.php/2012031247361/Small-Molecules/Reviva-Pharmaceuticals-Announces-Enrollment-of-Patients-in-Phase-2-Clinical-Study-of-RP5063-for-the-Treatment-of-Schizophrenia-and-Schizoaffective-Disorder.html. 

External links





Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:RP-5063&oldid=3711045"